Brian A. Markison serves as the Chief Executive Officer at Lantheus Holdings Inc., a position he has held since joining the company in 2019. With an extensive background in the pharmaceutical and healthcare industries, Markison has been instrumental in steering Lantheus towards significant growth and innovation. Prior to Lantheus, he was the President and CEO of AMAG Pharmaceuticals, where he successfully led the company through a period of strategic transformation, enhancing its portfolio and market presence. Markison's career is marked by a series of notable achievements, including driving the development and commercialization of multiple successful products. At AMAG, he oversaw the launch of several key products that bolstered the company's revenue and solidified its position in the women's health and hematology markets. His strategic vision and leadership skills have been pivotal in navigating complex market dynamics and regulatory environments. Markison holds a Bachelor of Science degree in Pharmacy from the Albany College of Pharmacy and a Master of Business Administration from the Isenberg School of Management at the University of Massachusetts Amherst. In his role at Lantheus Holdings Inc., Markison is focused on advancing the company's mission to improve patient outcomes through the development of innovative diagnostic and therapeutic solutions. Under his leadership, Lantheus has expanded its portfolio of radiopharmaceuticals and diagnostic agents, positioning the company as a leader in the nuclear medicine field. Markison's commitment to fostering a culture of excellence and innovation continues to drive Lantheus forward, ensuring its ability to meet the evolving needs of healthcare providers and patients worldwide.